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The epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein that has been identiﬁed as a marker
of cancer-initiating cells. EpCAM is highly expressed on most carcinomas, and transient silencing of EpCAM
expression leads to reduced oncogenic potential. To silence the EpCAM gene in a persistent manner via targeted
DNA methylation, a low activity mutant (C141S) of the CpG-speciﬁc DNA methyltransferase M.SssI was coupled
to a triple-helix-forming oligonucleotide (TFO-C141S) speciﬁcally designed for the EpCAM gene. Reporter
plasmids encoding the green ﬂuorescent protein under control of different EpCAM promoter fragments were
treated with the TFO-C141S conjugate to determine the speciﬁcity of targeted DNA methylation in the context
of a functional EpCAM promoter. Treatment of the plasmids with TFO-C141S resulted in efﬁcient and speciﬁc
methylation of the targeted CpG located directly downstream of the triple helix forming site (TFS). No background
DNA methylation was observed neither in a 700 bp region of the EpCAM promoter nor in a 400 bp region of the
reporter gene downstream of the TFS. Methylation of the target CpG did not have a detectable effect on promoter
activity. This study shows that the combination of a speciﬁc TFO and a reduced activity methyltransferase variant
can be used to target DNA methylation to predetermined sites with high speciﬁcity, allowing determination of
crucial CpGs for promoter activity.
INTRODUCTION
The epithelial cell adhesion molecule (EpCAM) is a mem-
brane glycoprotein that is highly expressed on most carcinomas.
Recently, EpCAM has gained renewed interest as a signal
transducer in carcinogenesis (1) and has been identiﬁed as a
marker of cancer-initiating cells in breast (2), pancreatic (3),
hepatocellular (4) and colon cancer (5). In the clinical setting,
EpCAM has become a target for carcinoma directed immuno-
therapy (6). Transient silencing of EpCAM expression utilizing
antisense or siRNA led to reduced proliferation, migration, and
invasiveness (7-10), illustrating the therapeutic potential of
EpCAM inhibition. However, as mRNA molecules are con-
stantly produced, RNA-based approaches require repeated
administration of the inactivating reagent. This study aims to
develop a tool to silence the EpCAM gene in a more persistent
manner via targeted DNA methylation.
It has been shown that the EpCAM promoter is differentially
methylated in lung adenocarcinoma (11), oral squamous cell
carcinoma (12), and colon cancer (13) and that EpCAM
expression is associated with the methylation status of the
promoter (11, 13, 14). For several cell lines, we and others have
demonstrated that treatment with DNA methyltransferase inhibi-
tors like 5-aza-2-deoxycytidine up-regulates the expression of
EpCAM (11, 14, 15). Moreover, after delivery of the CpG-
speciﬁc prokaryotic DNA (cytosine-5) methyltransferase M.SssI
into EpCAM positive ovarian carcinoma cells, methylation of
the EpCAM gene resulted in sustained repression of EpCAM
expression (14). However, if DNA methylation can be targeted
with high speciﬁcity to predetermined sites in the genome, DNA
methylation-mediated gene silencing can be fully exploited as
a research tool and further developed as a therapeutic approach.
Application of targeted DNA methylation to silence EpCAM
expression would have many advantages over transient silencing
by siRNA. First, the maintenance DNA methyltransferases in
the cell will copy the new methylation mark in the absence of
the exogenous methyltransferase, so a single hit is expected to
be sufﬁcient to silence the EpCAM gene in a permanent way.
Second, targeted DNA methylation needs to affect just two
copies of the EpCAM gene rather than the numerous copies of
mRNA present in each cell.
Targeted DNA methylation, pioneered by Xu and Bestor (16),
traditionally employed DNA methyltransferases genetically
fused to sequence speciﬁc DNA binding proteins, zinc ﬁnger
proteins, which acted as targeting domains (16-19). As an
alternative to zinc ﬁnger proteins, triple-helix-forming oligo-
nucleotides (TFO) can be used as targeting domains. TFOs
binding by sequence-speciﬁc Hoogsteen hydrogen bonds in the
major groove of double-stranded DNA have been used to target
cleaving (20), cross-linking reagents (21) or anticancer agents
(22) to unique target sequences. The advantages of TFOs relative
to zinc ﬁnger proteins are the easy synthesis and low cost. The
drawbacks are the requirements for an in vitro coupling step to
covalently link the effector protein to the TFO and the limitation
of binding to oligopurine-oligopyrimidine sequences. However,
the latter limitation is mitigated by the over-representation of
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human genes (23-25). Recently, we and others have shown
that coupling of a TFO to the restriction enzymes scPvuII (20)
and Mun-I is feasible (Geel et al., manuscript in preparation).
To explore the possibility of targeting methylation to speciﬁc
DNA sequences using a TFO as targeting domain, we coupled
a variant of the methyltransferase M.SssI to a TFO speciﬁcally
designed for the EpCAM gene (26). This M.SssI variant, named
C141S throughout this paper, carried the C141S and C368A
substitutions and a C-terminal 6xHis-Cys tag. In this variant
the internal cysteines were thus replaced and the C-terminal
Cys was introduced to allow coupling of the methyltransferase
to the TFO. Although one of the replaced cysteines (C141S) is
the active site cysteine, the C141S mutation does not fully
abolish the methyltransferase activity; the mutant enzyme has
2-5% of the wild type (WT) activity (27). DNA binding afﬁnity
of the C141S variant is similar to that of the WT enzyme (28).
Coupling of C141S to the TFO did not affect activity of the
enzyme, and binding speciﬁcity of the TFO-C141S conjugate
to the DNA was dominated by the TFO. Site-speciﬁc methy-
lation by the TFO-C141S conjugate was demonstrated using
a plasmid containing a 43 bp segment of the EpCAM promoter
encompassing the TFS and a target CpG (26). To investigate
targeted methylation in the context of a functional EpCAM
promoter, reporter plasmids encoding the Green Fluorescent
Protein (GFP) under control of different EpCAM promoter
fragments (29) were treated with the TFO-C141S conjugate
and assayed for DNA methylation and gene expression.
In this study we demonstrate that a TFO coupled to a reduced
activity DNA methyltransferase can be directed to a predeter-
mined site to induce targeted methylation, allowing determi-
nation of crucial CpGs for promoter activity.
EXPERIMENTAL PROCEDURES
Methylation of Plasmids with TFO-C141S. The p39E
plasmid and its promoter deletion derivatives (29) are schemati-
cally depicted in Figure 1A. These plasmids encode GFP under
control of a 3.4 kb fragment of the EpCAM promoter.
Construction of the plasmids expressing WT M.SssI or C141S,
puriﬁcation of the enzymes (14) and coupling of the 5′-
TTTTTTTTTTTTTTTCTCTCTTTT-3′ TFO to M.SssI(C141S)
were done as described (26). Plasmids were incubated with
5-fold molar excess of TFO-C141S, M.SssI, C141S, or TFO
in a buffer containing 20 mM Tris, 50 mM NaCl, 10 mM MgCl2,
pH 7.9, with or without 640 µM S-adenosylmethionine (SAM)
(New England Biolabs, Ipswich, MA) at 30 °C. The reaction
was terminated after 20 h by heat inactivation at 65 °C for 20
min, and plasmids were puriﬁed by Qiagen PCR puriﬁcation
kit (Qiagen, Benelux B.V., Venlo, The Netherlands).
To test the involvement of enzyme activity in TFO-C141S-
induced relaxation of supercoiled plasmid DNA, C141S and
TFO-C141S were heat-inactivated by incubation at 65 °C for
20 min. Plasmid p39E was incubated with active or inactivated
C141S or TFO-C141S for 15 or 30 min or 1, 2.5, 5, or 20 h
at 30 °C. Then the reaction was stopped by 10% SDS and
digestion with proteinase K.
Transfection. The SKOV3 (HTB-77) cell line was purchased
from ATCC (Manasas, VA) and cultured according to ATCC
recommendations. SKOV3 cells were seeded 100000/well in
24-wells plates, and transfection was performed at 60-80%
conﬂuency using SAINT-2:DOPE (SD, 0.75 mM) (Synvolux
Therapeutics, Groningen, The Netherlands) (30). Pretreated
plasmid DNA (250 ng) in 25 µL of Hanks balanced salt solution
was added to 5 µL of SD ﬁlled up with 20 µL of HBS. Within
15 min the complex was diluted in 200 µL of serum-free culture
medium and added directly to the cells. After3ho fincubation
at 37 °C, in 5% CO2, serum containing medium was added.
After 48 h, cells were harvested and GFP expression was
measured by ﬂow cytometry (Beckton Dickenson Bioscience
Calibur, San Jose, CA).
DNA Methylation Analysis. Plasmid DNA (250 ng) me-
thylated in vitro by TFO-C141S was treated with sodium
Figure 1. Schematic overview of EpCAM promoter fragments in the GFP reporter plasmids. (A) Plasmid p39E encompasses the GFP gene under
control of 3.4 kb of the EpCAM promoter. The Triple helix Forming Site (TFS) and sequences differing from the targeted TFS by only three or
four mismatches (3MM or 4MM) are indicated. CpGs are depicted by vertical bars. The transcription start site (TSS) corresponds to position +1.
The location of the amplicons analyzed for DNA methylation are indicated (not drawn to scale). (B) Sequence of one strand of bisulﬁte converted,
fully methylated DNA of the TFS amplicon. All cytosines in CpG combination are assumed to be methylated and therefore not converted by
bisulﬁte treatment. The CpGs are numbered and depicted in green. The TFS is shown in red, containing three Cs that have been converted to Ts.
CpG number 7 is the targeted CpG.
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EZ DNA Methylation-Gold kit (Zymo, Baseclear Lab Products,
Leiden, The Netherlands). Bisulﬁte speciﬁc primers void of any
CpG were used to obtain ampliﬁcation products (amplicons)
unbiased for the methylation status. Primer sequences for the
TFS amplicon were 5′-AATAATATAGTGTGTTGTGATTT-
3′ (forward) and 5′-CCTATAATCCCAACTACTAA-3′ (re-
verse). (The PCR product is shown in Figure 1B.) Two
overlapping amplicons were selected to cover a 700 bp region
directly downstream of the TFS in the EpCAM promoter. Primer
sequences for the ﬁrst amplicon were 5′-ACCTCCCCAATAAC-
TAAAATTAC-3′ (forward) and 5′-TTGAAGATTTTGTGT-
TGAGATTT-3′ (reverse). For the second one, they were 5′-
AGTGTTTTGGAAGGTTTTTTGT-3′ (forward) and 5′-
AAATTAAAAAAATAAATAAACTCCC-3′ (reverse). Primers
used for the GFP amplicon were 5′-GGGGTGGTGTT-
TATTTTG-3′(forward)and5′-CTCCAACTTATACCCCAAAAT-
3′ (reverse). The location of the amplicons in the plasmids is
indicated in Figure 1A. PCR conditions were as follows: 95 °C
for 15 min, followed by 35 cycles of 95 °C for 45 s, 53-56 °C
for 45 s, 72 °C for 45 s, and ﬁnished with 72 °C for 10 min.
PCR fragments were puriﬁed from gels using the DNA
extraction kit (Qiagen) and cloned into pCR 2.1-TOPO TA
vector (Invitrogen, Breda, The Netherlands). Following trans-
formation, plasmids were isolated from individual bacterial
colonies using the Qiaprep Spin Miniprep kit (Qiagen) and
subjected to restriction analysis. Clones with the expected
structure were sequenced.
RESULTS
Targeted DNA Methylation of the EpCAM Promoter
in p39E. To test the targeting speciﬁcity of the TFO-C141S
conjugate in the context of a functional EpCAM promoter, p39E
containing the 3.4 kb EpCAM promoter was treated with
TFO-C141S. Three independent TFO-C141S treatments re-
sulted in 57% (n ) 7), 89% (n ) 9), and 75% (n ) 8)
methylation of CpG7 (Figure 1B) located directly downstream
the TFS (Table 1A). Of the 24 clones analyzed, 18 showed
methylation of CpG7. Only three clones were devoid of
methylation. One clone showed methylation only of CpG9, and
two clones showed methylation only of CpG5 located ∼40 bp
upstream of the TFS. Four of the 18 positive clones showed
methylation of CpG5 and CpG7, and one of these clones also
showed methylation of CpG6. CpG1, -2, -3, -4, and -8 within
the TFS amplicon (Figure 1B) were not methylated in the clones
sequenced. Importantly, apart from one sporadic methylation
event, no methylation was observed downstream of the TFS
neither in the EpCAM promoter (EpCAM ﬁrst and second
amplicon, Table 1A) nor in the part of the GFP gene (GFP
amplicon). In the control samples, obtained by treating p39E
with WT M.SssI, all CpGs analyzed were methylated (Table
1B), whereas treatment with the less active C141S variant
resulted in random methylation.
GFP Expression from the EpCAM Promoter after
Pretreatment with TFO-C141S. After observing that the
TFO-C141S conjugate induced targeted DNA methylation, we
tested if methylation of this single CpG (CpG7) is sufﬁcient to
inhibit EpCAM promoter activity. Hence, all treated plasmids
were transfected in SKOV3 cells to determine GFP expression.
The three independent treatments of p39E with TFO-C141S
showed 46% ( 20 (n ) 3), 48% ( 16 (n ) 3), and 57% ( 6
(n ) 2) GFP down-regulation (see Figure 2A for a representative
experiment). Transfection of plasmids treated with untargeted
M.SssI or untargeted C141S resulted in 91% ( 1 and 27% (
1 GFP down-regulation, respectively, whereas treatment with
just the TFO did not inﬂuence GFP expression. Transfection
of p39E treated with a 100-fold excess of TFO in the presence
of TFO-C141S (competition sample in Figure 2A) showed 24%
( 17 down-regulation of GFP, which is approximately 33%
less than the value obtained with TFO-C141S only, indicating
that targeting was dependent on the TFO. These observations
suggested that methylation of a single CpG was sufﬁcient to
reduce EpCAM promoter activity.
Down-Regulation of GFP Gene Expression by
TFO-C141S in the Absence of TFS or Methyl Donor. To
investigate if the reduction in GFP expression was indeed due
to targeted DNA methylation, deletion derivatives of p39E (29)
(p15-2, p7-2, p4-1, and p11-1) (Figure 1A) were treated with
TFO-C141S and transfected in SKOV3 cells to determine GFP
expression. Plasmids p15-2 and p7-2 contained the TFS, whereas
plasmids p4-1 and p11-1 lacked this sequence. In addition to
the targeted TFS, the EpCAM promoter region contains four
sites, which differ from the targeted TFS only by three or four
mismatches (3MM or 4MM, as indicated in Figure 1A).
Plasmids p7-2 and p4-1 treated with TFO-C141S showed 51%
( 4 and 46% ( 8 GFP down-regulation, respectively (Figure
2B). The latter result was unexpected, as plasmid p4-1 lacked
the TFS. To exclude the possibility that down-regulation was
caused by binding of TFO-C141S to the TFS 4MM site (Figure
1A) present in p4-1, plasmids p15-2 and p11-1 were treated
with TFO-C141S and transfected into SKOV3 cells. Plasmid
p15-2 contains the TFS and two TFS-like sites, whereas from
p11-1 all potential binding sites had been deleted (Figure 1A).
Both pretreated plasmids showed approximately 45% reduction
of GFP expression compared to their untreated controls (data
not shown).
To exclude that the reduction in GFP expression was not
caused by a speciﬁc DNA methylation, the methylation status
of the deletion derivatives of p39E was analyzed. Treatment of
p15-2 with TFO-C141S resulted in 36% methylation of CpG7
(5/14 clones), and one clone showed methylation of CpG5
(Table 2). Apart from one sporadic event, deletion derivatives
p7-2 and p4-1 and p11-1 did not show methylation in the
downstream amplicons. These results conﬁrm the speciﬁcity of
targeted methylation by TFO-C141S.
Table 1. Targeted DNA Methylation of p39E by TFO-C141S
(A) Methylation Status of Bisulﬁte Amplicons for p39E
Treated with TFO-C141S and the Methyl Donor SAM
a
(B) Methylation Status of Bisulﬁte Amplicons for p39E
Treated with the Controls As Indicated
a Results of bisulﬁte sequencing.
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of the conjugate still being attached to the plasmid, p39E was
also treated with TFO-C141S in the absence of S-adenosyl-
methionine (SAM). No difference in reduction of GFP expres-
sion was observed between samples treated with or without the
methyl donor (Figure 2C). To conﬁrm that reduction in GFP
expression was not caused by aspeciﬁc DNA methylation,
plasmid p39C encoding GFP under control of the CMV
promoter without a TFS-like sequence was subjected to
TFO-C141S treatment. Also for p39C, GFP expression was
reduced while no difference was observed between treatments
in the presence or in the absence of SAM (Figure 2C).
TFO-C141S Induced Relaxation of Supercoiled
Plasmids. Because GFP expression from the transfected pre-
treated plasmids seemed to be independent of their methylation
status, we examined the conformation of the pretreated plasmids.
Treatment of p39E with TFO-C141S with or without methyl
donor led to relaxation of the supercoiled plasmid (Figure 3A,
lanes 6, 7). The deletion plasmid p11-1 behaved in the same
way; treatment with TFO-C141S caused relaxation (lane 12),
whereas treatment with only the TFO, M.SssI, or C141S did
not affect conformation of the plasmid. Interestingly, the
presence of excess TFO seemed to protect to some extent the
plasmid from conversion into the relaxed form (lane 8).
The phenomenon of conformation change appeared to be
general: treatment of p39C, p7-2, and p4-1 with TFO-C141S
also caused a conversion to the relaxed form (data not shown).
To exclude the possibility that the slower electrophoretic
mobility was caused by TFO-C141S still being attached to the
plasmid, the TFO-C141S treated samples were digested with
proteinase K. No difference in conformation was observed
between the plasmids with and without proteinase K treatment
(data not shown), indicating that C141S was not attached to
the plasmid.
Because it has been reported that M.SssI can display
topoisomerase activity (31), TFO-C141S was heat-inactivated
before treatment of p39E. Treatment of the plasmid p39E with
heat-inactivated TFO-C141S did not result in conformation
change, whereas treatment with active TFO-C141S led to
Figure 2. Effect of TFO-C141S treatment on GFP expression in EpCAM positive SKOV3 cells. (A) Relative GFP expression measured 48 h after
transfection of pretreated p39E. Plasmid p39E was treated as indicated: p39E ) treatment without TFO-C141S, treated with TFO only, with
untargeted M.SssI or C141S, with the TFO-C141S conjugate or with 100-fold excess of TFO and TFO-C141S ()competition). The value obtained
with p39E without TFO-C141S was taken as 100%. Shown is the average GFP expression ((SD) of one representative transfection performed in
triplicate. (B) Relative GFP expression measured 48 h after transfection of pretreated deletion derivatives p7-2 and p4-1. For each derivative, the
values obtained with samples treated without TFO-C141S were taken as 100%. Shown is the average GFP expression ((SEM) of the mean of
three independent transfections performed in triplicate. (C) Relative GFP expression was measured 48 h after transfection of pretreated p39E or
p39C. Treatments were as indicated: (+)o r( -) indicates the presence or absence of the methyl donor (SAM). Shown is the average GFP expression
((SEM) of the mean of three independent transfections performed in triplicate.
Table 2. Targeted DNA Methylation of p39E Deletion Derivatives
by TFO-C141S
a
a Methylation status of bisulﬁte amplicons for the deletion derivatives
p39E treated with TFO-C141S and the methyl donor SAM. Shown are
the results of bisulﬁte sequencing. n ) number of clones analyzed.
Below the lollipop: the percentage of clones of which the CpG was
methylated. Open lollipop: 0% methylated CpG. Black lollipop: 100%
methylated CpG.
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3B). This change in conformation was dependent on the duration
of the treatment; i.e., longer treatment resulted in a less
supercoiled and a more relaxed conformation. Treatment of
p39E with C141S or heat-inactivated C141S showed no
conformation change.
On the basis of the observation that excess TFO could protect
the p39E plasmid from TFO-C141S mediated relaxation
(Figure 3A, lanes 6, 7, 8), we investigated this protection in
more detail. Treatment of p39E, as well as p39C with
TFO-C141S only, showed efﬁcient relaxation already after
2.5 h of treatment (Figure 3C). In the presence of excess TFO,
again both plasmids showed relaxation although the efﬁciency
was somewhat less (Figure 3C). To further prove that the
presence of the TFS is not necessary for relaxation, plasmids
with a different backbone were subjected to TFO-C141S
treatment. Although the backbones did not contain any TFS-
like sequences, we again observed an increase in the relaxed
conformation when the incubation time with TFO-C141S was
increasing (data not shown).
DISCUSSION
In this study, we demonstrated that a DNA methyltransferase
can be directed to a predetermined site by a covalently attached
TFO and that TFO-mediated targeting can be used to induce
targeted methylation. Because the TFO binds antiparallel to the
sense strand of the TFS in the EpCAM promoter and C141S is
coupled to the 5′-end of the TFO, C141S should orient
downstream of the TFS. We therefore expected CpG7 (Figure
1B) to be the main target for C141S. Indeed, treatment of
reporter plasmids with TFO-C141S resulted in efﬁcient (18/
24 clones) and speciﬁc (14/21 clones) methylation of CpG7
located directly downstream the TFS. These results indicate that
binding speciﬁcity of TFO-C141S is dominated by the TFO.
The 24 nucleotide long TFO used in this study contains three
cytosines. Speciﬁc binding of the TFO requires protonation of
the three cytosines to form the C+·GC triplets (pH < 6) (21).
However, treatment of the plasmids with TFO-C141S was
performed under conditions optimal for methylation (pH 7.9),
i.e., at a pH higher than required for efﬁcient formation of
C+·GC triplets. Despite the suboptimal annealing conditions,
efﬁcient DNA methylation was observed at the target site.
The 3.4 kb EpCAM promoter encompasses four sites that
are similar to the targeted TFS (i.e., differing only at three or
four positions); hence, they would be expected to be potential
sites of nontargeted binding and methylation. To test this
possibility, deletion derivatives of p39E containing (p15-2, p7-
2) or lacking the TFS (p4-1, p11-1) were treated with
TFO-C141S. Despite the presence of a possible binding site
in amplicon 1, CpG7 was preferentially methylated (18/24
clones), whereas no methylation was observed for amplicon 1
in all treated plasmids. Moreover, deletion derivatives lacking
the TFS (p4-1, p11-1) displayed no methylation in the analyzed
areas. We thus conclude that the TFO directs C141S only to its
predetermined site.
Next, we investigated if this site-speciﬁc DNA methylation
in the EpCAM promoter is sufﬁcient to induce inhibition of
gene expression. It has been shown that methylation of one or
a few CpGs within a promoter might be sufﬁcient to repress
transcription. Transfection of a reporter plasmid under control
of the p53 promoter in which a single CpG was methylated in
vitro by HhaI showed 85% down-regulation of the reporter gene
(32). Unexpectedly, in our experiments TFO-C141S treatment
of all GFP reporter plasmids resulted in lower GFP expression,
Figure 3. Effect of TFO-141S treatment on plasmid conformation. (A) Agarose gel electrophoresis of plasmids p39E and p11-1 treated with the
TFO, WT M.SssI, C141S, or the TFO-C141S conjugate: lane 1, untreated; lane 2, without TFO-C141S; lane 3, TFO; lane 4, M.SssI; lane 5,
C141S; lane 6, TFO-C141S; lane 7, TFO- C141S without SAM; lane 8, 100-fold excess of TFO and TFO-C141S; lane 9, marker; lane 10,
without TFO-C141S; lane 11, C141S; lane 12, TFO-C141S. (B) Agarose gel electrophoresis of plasmid p39E treated with active and heat-
inactivated C141S and TFO-C141S. The supercoiled plasmid was incubated at 30 °C for different time points as indicated above the lanes (hours).
Then the samples were deproteinized before electrophoresis as described in Experimental Procedures. (C) Agarose gel electrophoresis of plasmid
p39C and p39E treated with the TFO-C141S conjugate only or in the presence of 100-fold excess of TFO. Plasmids were incubated as in part B.
Lane a is puriﬁed plasmid.
Gene Speciﬁc DNA Methylation Bioconjugate Chem., Vol. 21, No. 7, 2010 1243and this phenomenon was independent of the methylation status
of the transfected plasmid. Gel electrophoresis revealed that
TFO-C141S treatment, in contrast to treatment with the enzyme
or TFO only, led to relaxation of the supercoiled plasmid,
explaining the observed GFP repression (33). Since plasmid
treatment with heat-inactivated TFO-C141S did not cause a
conformation change of the plasmid, we might conclude that
the observed relaxation is probably caused by topoisomerase
activity of C141S. Matsuo et al. described that M.SssI contains
both methylase and topoisomerase activities (31). However, the
observed topoisomerase activity was only displayed by the
TFO-C141S conjugate and not after treatment with the TFO
only or with C141S only. Independent of the presence of the
TFS, all plasmids treated with the TFO-C141S conjugate
showed relaxation of the plasmid: the observed ratio of
supercoiled versus relaxed plasmid conformation was decreasing
when the treatment time was prolonged. Somehow, the chemical
coupling of the TFO with the enzyme seems to change the
conformation of the enzyme, thereby uncovering the catalytic
topoisomerase domain. It requires further research to determine
which amino acid should be replaced to abolish this activity.
A puzzling observation of this study was that there was no
signiﬁcant difference in GFP down-regulation between plasmids
treated in the presence or absence of the methyl donor. A
possible explanation might be that the CpGs targeted in this
study do not play a role in the epigenetic regulation of the
EpCAM gene. Indeed, recent observations (11, 14, 15) suggest
that the CpGs, which display differential methylation, are located
further downstream (approximately -400 to +280 bps) of the
TFS, which is located around -917. Currently, we are inves-
tigating which CpGs are crucial in regulating EpCAM gene
expression. The important CpGs can then be targeted for induced
DNA methylation.
In summary, the data obtained with the TFO-C141S
conjugate offer a novel approach for targeted DNA methylation.
The combination of a speciﬁc TFO and the reduced methyl-
transferase activity of the M.SssI mutant C141S allowed us to
target methylation predominantly to a speciﬁc DNA sequence
without signiﬁcant background methylation. Because of the
ﬂexibility provided by the use of TFOs as targeting domain,
this approach appears to be a promising tool in both research
and therapeutic areas.
ACKNOWLEDGMENT
This work was supported by Grants QRLT-2001-0448 and
COOP-CT-2005-017984 of the European Commission’s Fifth
and Sixth Framework Programmes, respectively. We thank Dr.
Bill Jack (New England Biolabs) for the original plasmid with
the M.SssI gene and Burcu Duycu for technical assistance.
LITERATURE CITED
(1) Maetzel, D., Denzel, S., Mack, B., Canis, M., Went, P., Benk,
M., Kieu, C., Papior, P., Baeuerle, P. A., Munz, M., and Gires,
O. (2009) Nuclear signalling by tumour-associated antigen
EpCAM. Nat. Cell Biol. 11, 162–171.
(2) Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison,
S. J., and Clarke, M. F. (2003) Prospective identiﬁcation of
tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A.
100, 3983–3988.
(3) Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L.,
Adsay, V., Wicha, M., Clarke, M. F., and Simeone, D. M. (2007)
Identiﬁcation of pancreatic cancer stem cells. Cancer Res. 67,
1030–1037.
(4) Yamashita, T., Forgues, M., Wang, W., Kim, J. W., Ye, Q.,
Jia, H., Budhu, A., Zanetti, K. A., Chen, Y., Qin, L. X., Tang,
Z. Y., and Wang, X. W. (2008) EpCAM and {alpha}-fetoprotein
expression deﬁnes novel prognostic subtypes of hepatocellular
carcinoma. Cancer Res. 68, 1451–1461.
(5) Dalerba, P., Dylla, S. J., Park, I. K., Liu, R., Wang, X., Cho,
R. W., Hoey, T., Gurney, A., Huang, E. H., Simeone, D. M.,
Shelton, A. A., Parmiani, G., Castelli, C., and Clarke, M. F.
(2007) Phenotypic characterization of human colorectal cancer
stem cells. Proc. Natl. Acad. Sci. U.S.A. 104, 10158–10163.
(6) Baeuerle, P. A., and Gires, O. (2007) EpCAM (CD326) ﬁnding
its role in cancer. Br. J. Cancer 96, 417–423.
(7) Munz, M., Kieu, C., Mack, B., Schmitt, B., Zeidler, R., and
Gires, O. (2004) The carcinoma-associated antigen EpCAM
upregulates c-myc and induces cell proliferation. Oncogene 23,
5748–5758.
(8) Osta, W. A., Chen, Y., Mikhitarian, K., Mitas, M., Salem, M.,
Hannun, Y. A., Cole, D. J., and Gillanders, W. E. (2004) EpCAM
is overexpressed in breast cancer and is a potential target for
breast cancer gene therapy. Cancer Res. 64, 5818–5824.
(9) Yanamoto, S., Kawasaki, G., Yoshitomi, I., Iwamoto, T., Hirata,
K., and Mizuno, A. (2007) Clinicopathologic signiﬁcance of
EpCAM expression in squamous cell carcinoma of the tongue
and its possibility as a potential target for tongue cancer gene
therapy. Oral Oncol. 43, 869–877.
(10) Du, W., Ji, H., Cao, S., Wang, L., Bai, F., Liu, J., and Fan,
D. (2009) EpCAM: a potential antimetastatic target for gastric
cancer. Dig. Dis. Sci. 1033–1038.
(11) Tai, K. Y., Shiah, S. G., Shieh, Y. S., Kao, Y. R., Chi, C. Y.,
Huang, E., Lee, H. S., Chang, L. C., Yang, P. C., and Wu, C. W.
(2007) DNA methylation and histone modiﬁcation regulate
silencing of epithelial cell adhesion molecule for tumor invasion
and progression. Oncogene 26, 3989–3997.
(12) Shiah, S. G., Chang, L. C., Tai, K. Y., Lee, G. H., Wu, C. W.,
and Shieh, Y. S. (2009) The involvement of promoter methylation
and DNA methyltransferase-1 in the regulation of EpCAM
expression in oral squamous cell carcinoma. Oral Oncology 45,
e1–e8.
(13) Yu, G., Zhang, X., Wang, H., Rui, D., Yin, A., Qiu, G., and He,
Y. (2008) CpG island methylation status in the EpCAM promoter
region and gene expression. Oncol. Rep. 20, 1061–1067.
(14) van der Gun, B. T., Wasserkort, R., Monami, A., Jeltsch, A.,
Rasko, T., Slaska-Kiss, K., Cortese, R., Rots, M. G., de Leij,
L. F., Ruiters, M. H., Kiss, A., Weinhold, E., and McLaughlin,
P. M. (2008) Persistent downregulation of the pancarcinoma-
associated epithelial cell adhesion molecule via active intra-
nuclear methylation. Int. J. Cancer 123, 484–489.
(15) Spizzo, G., Gastl, G., Obrist, P., Fong, D., Haun, M.,
Grunewald, K., Parson, W., Eichmann, C., Millinger, S., Fiegl,
H., Margreiter, R., and Amberger, A. (2007) Methylation status
of the Ep-CAM promoter region in human breast cancer cell
lines and breast cancer tissue. Cancer Lett. 246, 253–261.
(16) Xu, G., and Bestor, T. (1997) Cytosine methylation targetted
to pre-determined sequences. Nat. Genet. 17, 376–378.
(17) Li, F., Papworth, M., Minczuk, M., Rohde, C., Zhang, Y.,
Ragozin, S., and Jeltsch, A. (2007) Chimeric DNA methyltrans-
ferases target DNA methylation to speciﬁc DNA sequences and
repress expression of target genes. Nucleic Acids Res. 35, 100–
112.
(18) Nomura, W., and Barbas, C. F. (2007) In vivo site-speciﬁc
DNA methylation with a designed sequence-enabled DNA
methylase. J. Am. Chem. Soc. 129, 8676–8677.
(19) Smith, A. E., and Ford, K. G. (2007) Speciﬁc targeting of
cytosine methylation to DNA sequences in vivo. Nucleic Acids
Res. 35, 740–754.
(20) Eisenschmidt, K., Lanio, T., Simoncsits, A., Jeltsch, A.,
Pingoud, V., Wende, W., and Pingoud, A. (2005) Developing a
programmed restriction endonuclease for highly speciﬁc DNA
cleavage. Nucleic Acids Res. 33, 7039–7047.
(21) Duca, M., Vekhoff, P., Oussedik, K., Halby, L., and Arimondo,
P. B. (2008) The triple helix: 50 years later, the outcome. Nucleic
Acids Res. 36, 5123–5138.
(22) Vekhoff, P., Halby, L., Oussedik, K., Dallavalle, S., Merlini,
L., Mahieu, C., Lansiaux, A., Bailly, C., Boutorine, A., Pisano,
1244 Bioconjugate Chem., Vol. 21, No. 7, 2010 van der Gun et al.C., Giannini, G., Alloatti, D., and Arimondo, P. B. (2009)
Optimized synthesis and enhanced efﬁcacy of novel triplex-
forming camptothecin derivatives based on gimatecan. Biocon-
jugate Chem. 20, 666–672.
(23) Wu, Q., Gaddis, S. S., Macleod, M. C., Walborg, E. F.,
Thames, H. D., DiGiovanni, J., and Vasquez, K. M. (2007) High-
afﬁnity triplex-forming oligonucleotide target sequences in
mammalian genomes. Mol. Carcinog. 46, 15–23.
(24) Goni, J. R., de la Cruz, X., and Orozco, M. (2004) Triplex-
forming oligonucleotide target sequences in the human genome.
Nucleic Acids Res. 32, 354–360.
(25) Goni, J., Vaquerizas, J., Dopazo, J., and Orozco, M. (2006)
Exploring the reasons for the large density of triplex-forming
oligonucleotide target sequences in the human regulatory regions.
BMC Genomics 7, 63.
(26) Maluszynska-Hoffman, M. (2009) Super-speciﬁcDNA meth-
yltion by a DNA methyltransferase coupled with a triple helix-
forming oligonucleotide. Dissertation. RWTH Aachen University,
Aachen, Germany. http://darwin.bth.rwth-aachen.de/opus3/voll-
texte/2009/2854/.
(27) Rathert, P., Rasko, T., Roth, M., Slaska-Kiss, K., Pingoud,
A., Kiss, A., and Jeltsch, A. (2007) Reversible inactivation
of the CG speciﬁc SssI DNA (cytosine-C5)-methyltransferase
with a photocleavable protecting group. ChemBioChem 8, 202–
207.
(28) Darii, M. V., Cherepanova, N. A., Subach, O. M., Kirsanova,
O. V., Rasko, T., Slaska-Kiss, K., Kiss, A., ville-Bonne, D.,
Reboud-Ravaux, M., and Gromova, E. S. (2009) Mutational
analysis of the CG recognizing DNA methyltransferase SssI:
insight into enzyme-DNA interactions. Biochim. Biophys. Acta
1794, 1654–1662.
(29) McLaughlin, P. M., Trzpis, M., Kroesen, B. J., Helfrich, W.,
Terpstra, P., Dokter, W. H., Ruiters, M. H., de Leij, L. F., and
Harmsen, M. C. (2004) Use of the EGP-2/Ep-CAM promoter
for targeted expression of heterologous genes in carcinoma
derived cell lines. Cancer Gene Ther. 11, 603–612.
(30) van der Gun, B. T., Monami, A., Laarmann, S., Rasko, T.,
Slaska-Kiss, K., Weinhold, E., Wasserkort, R., de Leij, L. F.,
Ruiters, M. H., Kiss, A., and McLaughlin, P. M. (2007) Serum
insensitive, intranuclear protein delivery by the multipurpose
cationic lipid SAINT-2. J. Controlled Release 123, 228–238.
(31) Matsuo, K., Silke, J., Gramatikoff, K., and Schaffner, W.
(1994) The CpG-speciﬁc methylase SssI has topoisomerase
activity in the presence of Mg
2+. Nucleic Acids Res. 22, 5354–
5359.
(32) Pogribny, I. P., Pogribna, M., Christman, J. K., and James,
S. J. (2000) Single-site methylation within the p53 promoter
region reduces gene expression in a reporter gene construct:
possible in vivo relevance during tumorigenesis. Cancer Res.
60, 588–594.
(33) Remaut, K., Sanders, N. N., Fayazpour, F., Demeester, J., and
De Smedt, S. C. (2006) Inﬂuence of plasmid DNA topology on
the transfection properties of DOTAP/DOPE lipoplexes. J.
Controlled Release 115, 335–343.
BC1000388
Gene Speciﬁc DNA Methylation Bioconjugate Chem., Vol. 21, No. 7, 2010 1245